A5026272602- SARS-CoV-2 and COVID-19 Research
- SARS-CoV-2 detection and testing
- Immunotherapy and Immune Responses
- Animal Virus Infections Studies
- Cancer Immunotherapy and Biomarkers
- Viral Infections and Immunology Research
- CAR-T cell therapy research
Abstract The coronavirus disease 2019 (COVID-19) pandemic continues to spread globally, highlighting the urgent need for safe and effective vaccines that could be rapidly mobilized immunize large populations. We report preclinical development of a self-amplifying mRNA (SAM) vaccine encoding prefusion stabilized severe acute respiratory syndrome 2 (SARS-CoV-2) spike glycoprotein demonstrate strong cellular humoral immune responses at low doses in mice rhesus macaques. homologous prime-boost...
Abstract SARS-CoV-2 has resulted in high levels of morbidity and mortality world-wide, severe complications can occur older populations. Humoral immunity induced by authorized vaccines wanes within 6 months, frequent boosts may only offer transient protection. GRT-R910 is an investigational self-amplifying mRNA (samRNA)-based vaccine delivering full-length Spike selected conserved non-Spike T cell epitopes. This study reports interim analyses for a phase I open-label dose-escalation trial...
Abstract The coronavirus disease 2019 (COVID-19) pandemic continues to spread globally, highlighting the urgent need for safe and effective vaccines that could be rapidly mobilized immunize large populations. We report preclinical development of a self-amplifying mRNA (SAM) vaccine encoding prefusion stabilized severe acute respiratory syndrome 2 (SARS-CoV-2) spike glycoprotein demonstrate potent cellular humoral immune responses at low doses in mice rhesus macaques. homologous prime-boost...